Atossa Genetics Receives 'Hold' Rating from Analysts

The biotech company's stock has a consensus recommendation of 'Hold' from research firms.

Mar. 14, 2026 at 10:50am

Got story updates? Submit your updates here. ›

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have earned a consensus recommendation of 'Hold' from the five research firms currently covering the company, according to Marketbeat Ratings. Two analysts have rated the stock as a 'sell', two have given it a 'buy' recommendation, and one has issued a 'strong buy' rating. The average 12-month price target among brokerages is $95.00.

Why it matters

Atossa Genetics is a clinical-stage biotech company focused on developing treatments and diagnostic products for breast cancer and other breast-related conditions. The 'Hold' rating from analysts suggests the stock may not have significant upside in the near term, despite the company's promising pipeline that includes its lead drug candidate Z-Endoxifen.

The details

Several analysts have recently weighed in on Atossa Genetics' stock. Weiss Ratings reiterated a 'sell (d-)' rating on the shares, while Ascendiant Capital Markets raised its price target from $116.25 to $120.00 and maintained a 'buy' rating.

  • Weiss Ratings reiterated its 'sell (d-)' rating on January 21, 2026.
  • Ascendiant Capital Markets raised its price target on December 8, 2025.

The players

Atossa Genetics Inc.

A clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions.

Weiss Ratings

A research firm that reiterated a 'sell (d-)' rating on Atossa Genetics' stock.

Ascendiant Capital Markets

A research firm that raised its price target on Atossa Genetics' stock to $120.00 and maintained a 'buy' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The 'Hold' rating on Atossa Genetics' stock suggests analysts see limited near-term upside, despite the company's promising pipeline targeting breast cancer and other breast conditions. Investors will be watching to see if the company can deliver positive clinical results and drive the stock higher.